Skip to content
Search

Latest Stories

NPA data highlights public's growing appreciation for community pharmacies

Consumer research reveals Britons are embracing community pharmacies as their healthcare settings

The National Pharmacy Association (NPA), released survey data today (30 October) which suggests Britons have a higher regard for community pharmacies than retail settings.


It also highlighted the level of awareness of pharmacies' healthcare duties, which range from NHS medicines consultations to monitoring blood pressure.

The survey conducted by Research Without Barriers involved 1680 adults in England from 20-23 October 2023.

The data showed that over 90 per cent of adults in England are aware that pharmacies offer each of these services.

The survey also suggested that 56 per cent of respondents find it appropriate to ask their local pharmacies for help to quit smoking, and 63 per cent would ask for a blood pressure check.

Stephen Fishwick, NPA Head of Communications, said that the new data shows an “encouraging level of public awareness and acceptance of community pharmacy-based clinical services”.

He added that there is a sense of “recognition that community pharmacists are highly trained healthcare professionals” but he also believes that there is still a “long way” to go.

“That’s why we encourage our members and pharmacy stakeholders to get involved with initiatives like Ask Your Pharmacist Week, which promote the convenient clinical care on offer in community pharmacies across the UK,” he said.

Moreover, a majority of the respondents chose words like “medicines”, “convenient”, “healthcare”, “minor illnesses”, “caring”, “consultations”, and “expert” to describe their associations with community pharmacists.

Janet Morrison, Community Pharmacy England's chief executive said: "The figures reaffirm the growing appreciation for the crucial role that local community pharmacy teams play and the critical nature of the skills and services offered by pharmacies.

"It’s evident that the public increasingly recognises community pharmacies as vital healthcare providers, offering services such as flu vaccinations and serving as convenient clinical healthcare settings: Government and the NHS must continue to build on this, ensuring these services are properly funded and that community pharmacies are sustainable for the future."

She said: "As we approach another difficult winter season in healthcare, the calls for increased core funding and more support for community pharmacy remain essential and we will continue to press these points.

"During this Ask Your Pharmacist Week, the focus is on highlighting the expertise of community pharmacists and the broader pharmacy team, helping to build that case. We encourage pharmacy owners, pharmacy teams, and LPCs in England to support this year’s campaign if they can.”

Ask Your Pharmacist Week runs from 30 October to 6 November. Held annually across the UK, it aims to raise awareness of pharmacy services and to prompt conversations with stakeholders at a local level about community pharmacy’s role and benefits.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less